OvaScience Prices Secondary Offering
OvaScience shares dropped early on Thursday after the company announced that it had priced its secondary offering of more than 7 million shares at $7 per share.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
OvaScience Inc. (NASDAQ: OVAS) shares dropped early on Thursday following the pricing of its secondary offering. The company announced that it has priced its secondary offering of 7.15 million shares at $7.00 per share. The offering is valued up to $50.05 million.
For some background: OvaScience is a global fertility company dedicated to improving treatment options for women around the world. OvaScience is discovering, developing and commercializing new fertility treatments because it believes women deserve more options.
Each OvaScience treatment is based on the company’s proprietary technology platform that leverages the breakthrough discovery of egg precursor (EggPC) cells — immature egg cells found inside the protective ovarian lining. The Augment treatment, a fertility option specifically designed to improve egg health, is available in certain in vitro fertilization (IVF) clinics in select international regions.
[nativounit]
OvaScience has commenced a non-commercial preceptorship training program with the OvaPrime treatment, which could increase a woman’s egg reserve, and is developing the OvaTure treatment, a potential next-generation IVF treatment that could help a woman produce healthy, young, fertilizable eggs without hormone injections. OvaScience treatments are not available in the United States.
Net proceeds to OvaScience from this offering are expected to be roughly $46.8 million, after deducting underwriting discounts and commissions and estimated offering expenses. OvaScience intends to use the proceeds from this offering to fund the commercial expansion of the Augment treatment in its key regions, Japan and Canada, the ongoing pre-commercial activities for the OvaPrime treatment and the OvaTure treatment, and working capital and other general corporate purposes.
Shares of OvaScience traded down more than 24% to $7.37 on Thursday, with a consensus analyst price target of $8.60 and a 52-week trading range of $4.53 to $39.29.
[wallst_email_signup]
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
